^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AR overexpression

    i
    Other names: AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
    Entrez ID:
    367
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    11ms
    Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma. (PubMed, Cancer Rep (Hoboken))
    This case confirms the potential efficacy of neratinib in HER2-positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 overexpression • AR overexpression • AR expression • HER-2 positive + HER-2 overexpression
    |
    Nerlynx (neratinib)
    11ms
    Beyond the Horizon: Rethinking Prostate Cancer Treatment Through Innovation and Alternative Strategies. (PubMed, Cancers (Basel))
    In due course, this results first in a pro-survival quiescence and then adaptation to ADT and CRPC progression. This constitutes a novel liability for PCa that we have targeted for several years and novel approaches.
    Journal
    |
    CHEK1 (Checkpoint kinase 1) • NEK1 (NIMA Related Kinase 1) • TLK1 (Tousled Like Kinase 1)
    |
    AR overexpression
    11ms
    Androgen receptor overexpression by immunohistochemistry in malignant salivary gland tumors in Tanzania. (PubMed, BMC Cancer)
    High-grade malignant SGTs and parotid gland location are associated with AR overexpression. This suggests that androgen deprivation therapy (ADT) has the potential to play a role in the management of advanced SGTs. However, large-scale studies that will include comprehensive molecular investigations and efficacy exploration of ADT are recommended to clarify our current findings and inform therapeutic options for patient with high grade and recurrent tumors.
    Retrospective data • Journal
    |
    AR (Androgen receptor)
    |
    AR overexpression • AR expression
    1year
    Small-molecule disruption of androgen receptor-dependent chromatin clusters. (PubMed, Proc Natl Acad Sci U S A)
    Current AR antagonists, such as enzalutamide, fail to provide long-term benefit for the mCRPC patients who have dramatic increases in AR expression...AR binding in the promoter, as well as 3D chromatin clustering, is needed for genes to respond. BG-15a/n represent promising agents for treating patients with relapsed AR-driven mCRPC tumors.
    Journal
    |
    AR (Androgen receptor)
    |
    AR overexpression • AR expression
    |
    Xtandi (enzalutamide)
    1year
    The Decreased Proliferation Capacity of Cardiomyocytes Induced By Androsterone Is Mediated By the Interactions Between Androgen Receptor and Retinoblastoma Protein. (PubMed, J Biochem Mol Toxicol)
    The repression of cell proliferation in response to androsterone was alleviated partly through the downregulation of Rb by siRNA transfection. In conclusion, AR repression to cell cycle and DNA replication-related gene expression, mediated by recruitment of Rb, may be one of the potential mechanisms of cell cycle arrest in cardiomyocytes induced by androsterone.
    Journal
    |
    AR (Androgen receptor)
    |
    AR overexpression
    1year
    Comprehensive characterization of the androgen receptor in male breast cancer (SABCS 2024)
    Our analysis suggests a strong association between AR expression and TP53 mutations, TMB-H, and PD-L1 positivity, immune cell infiltration, immune checkpoint and stem cell-related gene. Also, T cell inflamed and IFNy score were inversely related. Further exploration of specific alterations and immune-oncology markers associated with AR expression may help in clinical trial design for male patients with BC.
    Tumor mutational burden • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CHEK2 (Checkpoint kinase 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD34 (CD34 molecule) • KLF4 (Kruppel-like factor 4) • POU5F1 (POU Class 5 Homeobox 1) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • FOXP3 (Forkhead Box P3)
    |
    TP53 mutation • TMB-H • TP53 wild-type • AR overexpression • AR expression • TP53 expression • FOXP3 expression
    |
    MI Tumor Seek™
    1year
    MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway. (PubMed, Cell Commun Signal)
    MYO6 has pro-tumor and Enz-resistant effects in CRPC, suggesting that targeting MYO6 may be beneficial for ENZ-resistant CRPC therapy through the AR/MYO6/FAK signaling pathway.
    Journal
    |
    AR (Androgen receptor) • MYO6 (Myosin VI)
    |
    AR overexpression • AR expression
    |
    Xtandi (enzalutamide)
    1year
    Social isolation promotes tumor immune evasion via β2-adrenergic receptor. (PubMed, Brain Behav Immun)
    Pharmacological inhibition of β2-AR signaling effectively enhanced CD8+ T cell anti-tumor immune responses and improved the efficacy of anti-PD-1 immunotherapy in the context of social isolation. Thus, our study uncovers a mechanism through which social isolation induces tumor immune evasion and offers potential directions for cancer immunotherapy in socially isolated patients.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    AR overexpression
    1year
    Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review. (PubMed, ESMO Open)
    Systemic treatments contribute to the survival of patients with salivary gland cancer at relapsed or newly advanced stages. The response to treatment is heavily influenced by histological subtype and treatment specificity.
    Review • Journal • Metastases
    |
    AR (Androgen receptor)
    |
    HER-2 overexpression • AR overexpression • AR expression • KIT expression
    |
    Herceptin (trastuzumab) • bicalutamide
    1year
    Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy. (PubMed, Clin Transl Oncol)
    AR-overexpression and its association with other genes could favor a transcriptomic signature set to aid in identifying patients suitable for TKI in monotherapy, rather than aggressive combinations, enhancing thus, precision and personalized therapeutic decisions.
    Retrospective data • Journal
    |
    AR (Androgen receptor)
    |
    AR overexpression • AR expression
    1year
    FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer. (PubMed, Cancers (Basel))
    Targeting FOXM1 in AR-low TNBC may render cancer cells incapable of clustering their centrosomes and impair their ability to generate excess centrosomes. Hence, our review illuminates FOXM1 as a potential actionable target for AR-low TNBC.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • AR (Androgen receptor) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKB (Aurora Kinase B) • FOXM1 (Forkhead Box M1) • KIFC1 (Kinesin Family Member C1) • ATAD2 (ATPase Family AAA Domain Containing 2) • CDCA8 (Cell Division Cycle Associated 8) • E2F1 (E2F transcription factor 1)
    |
    AR overexpression
    1year
    The prognostic significance of androgen receptor expression in gliomas. (PubMed, Sci Rep)
    Higher AR expression levels are associated with higher grade disease and histopathologic features predicting poorer prognosis in lower grade gliomas. Higher gene expression in LGG patients is correlated with poor prognosis but not in the glioblastoma cohort suggesting saturated expression/functions of AR in glioblastoma.
    Journal
    |
    AR (Androgen receptor)
    |
    AR overexpression • AR expression • AR underexpression